• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Tetragenetics, MedImmune collaborate on ion channel drug discovery program

Tetragenetics, MedImmune collaborate on ion channel drug discovery program

January 8, 2015
CenterWatch Staff

Tetragenetics, an emerging biotechnology company based in Cambridge, Mass., will collaborate with MedImmune, the global biologics R&D arm of AstraZeneca, on antibody drug discovery research. Specifically, Tetragenetics will use its proprietary ion channel production technology, SionX, to produce up to five ion channel antigens for MedImmune's antibody drug discovery programs.

Ion channels are complex membrane proteins which are linked to a variety of human diseases, such as those involving inflammatory conditions. The use of Tetragenetics' technology to produce ion channel antigens will complement MedImmune's focus on antibody drug discovery, helping to develop new therapeutics targeting unmet medical needs.

Traditionally, ion channels have been difficult to express in standard cell lines and the low level of expression has made generation of antibodies against ion channels difficult. Using the Tetragenetics technology, high density expression of recombinant ion channels can be achieved which enables antibody drug discovery.

"Ion channels represent a diverse family of proteins, which have significant linkage to disease," said Herren Wu, vice president, R&D, global head of antibody discovery and protein engineering, MedImmune. "Isolating functional antibodies against these ion channel targets opens the possibility of developing therapeutic antibodies against this important target class, particularly when combining MedImmune's antibody discovery capabilities to the technology. We anticipate this will provide an important opportunity to develop new therapeutics to treat human diseases."

MedImmune will be provided with target ion channel antigens on a non-exclusive basis. Tetragenetics will receive up-front license fees, research funding and milestone payments associated with preclinical and clinical development as well as potential product sales.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing